Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

Date publication

octobre 2022

Journal

Clinical oncology (Royal College of Radiologists (Great Britain))

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROY Catherine , Dr VERNEREY Dewi

Tous les auteurs :
Le Roy C, Vernerey D, Evin C, Richard S, Crespel C, Samaille T, Le Tourneau C, Huguet F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36207237

Résumé

The EXTREME regimen is the standard for recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). However, many patients have a poor performance status and/or comorbidities, making them unfit for this regimen. We have treated them with carboplatin and cetuximab (simplified EXTREME regimen) since 2007. Our aim was to assess the efficacy and tolerance of this regimen in this frail population.

Mots clés

Carboplatin, EXTREME, cetuximab, elderly, head and neck squamous cell carcinoma, recurrent and/or metastatic

Référence

Clin Oncol (R Coll Radiol). 2022 10 4;: